Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer

    loading  Checking for direct PDF access through Ovid


PurposeWe evaluated the efficacy and tolerability of oral vinorelbine plus trastuzumab (OV + T) in Her2 positive advanced breast cancer as first line chemotherapy or after progressing on earlier treatment.Patients and methodsThirty consecutive patients (median age: 59 years) were included. Patients received OV in a dose of 60 mg/m2 on day 1 and 8, q = 21, without dose escalation. Trastuzumab was administered every 3 weeks at a dose of 6 mg/kg bodyweight after a loading dose of 8 mg/kg. Response was evaluated every three cycles using UICC criteria. Time to progression (TTP) and overall survival (OS) were estimated using the Kaplan-Meier product limit method. A multivariate analysis was performed to evaluate factors potentially influencing response rate and TTP.ResultsMedian time of observation was 20 months. We observed a complete response in 18% of patients, partial remission in 50%, stable disease ≥ 6 months in 21%, and progressive disease in 11%. TTP was median 9 months. OS was not reached. Response rate and TTP were influenced by line of treatment only. The main toxicities consisted of neutropenia and nausea.ConclusionsOV + T appears to be an effective and safe treatment option in advanced breast cancer at the dose and schedule chosen.

    loading  Loading Related Articles